Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06452160 | RECRUITING | Mesothelioma

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Sponsor:

BridGene Biosciences Inc.

Brief Summary:

The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.

Condition or disease

Mesothelioma

Epithelioid Hemangioendothelioma(EHE)

Solid Tumor

Intervention/treatment

BGC515

Phase

PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 103 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
Actual Study Start Date : 2024-06-27
Estimated Primary Completion Date : 2027-06
Estimated Study Completion Date : 2027-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Having signed the written Informed Consent Form
  • * Male or female aged ≥18 years
  • * Life expectancy ≥12 weeks
  • * Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1
  • * Dose escalation phase: Histologically or cytologically confirmed locally advanced or metastatic mesothelioma (MM), epithelioid hemangioendothelioma (EHE), or other advanced solid tumors who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care
  • * Dose expansion phase: Histologically or cytologically confirmed locally advanced or metastatic MM, EHE, etc. regardless of Hippo signaling pathway abnormalities, or other advanced solid tumors with Hippo signaling pathway abnormalities, who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care
  • * At least one measurable lesion
Exclusion Criteria
  • * Previous or current use of transcriptional enhanced associate domain (TEAD) inhibitors
  • * Inadequate wash-out of prior therapies described per protocol
  • * Patients with severe or unstable systemic disease, unstable or symptomatic Central Nervous System (CNS) metastasis
  • * Clinically significant cardiovascular disease as defined in the protocol
  • * Women who are pregnant or breastfeeding
  • * Hypersensitivity to the active pharmaceutical ingredient or any excipient of BGC515
  • * Study staff member or relative of a study staff member directly related to this clinical trial, or a subordinate of the Investigator in this trial or an employee of the Sponsor, though not directly related to this trial
  • * Serious systemic diseases or laboratory abnormalities or other conditions that, at the Investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial.
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

Location Details

NCT06452160

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Texas

MD Anderson Cancer Center

Houston, Texas, United States, 77030